453 related articles for article (PubMed ID: 30718506)
1. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
Xue Y; Meehan B; Fu Z; Wang XQD; Fiset PO; Rieker R; Levins C; Kong T; Zhu X; Morin G; Skerritt L; Herpel E; Venneti S; Martinez D; Judkins AR; Jung S; Camilleri-Broet S; Gonzalez AV; Guiot MC; Lockwood WW; Spicer JD; Agaimy A; Pastor WA; Dostie J; Rak J; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):557. PubMed ID: 30718506
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
[TBL] [Abstract][Full Text] [Related]
3. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
4. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.
Tagal V; Wei S; Zhang W; Brekken RA; Posner BA; Peyton M; Girard L; Hwang T; Wheeler DA; Minna JD; White MA; Gazdar AF; Roth MG
Nat Commun; 2017 Jan; 8():14098. PubMed ID: 28102363
[TBL] [Abstract][Full Text] [Related]
5. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
6. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
Tian Y; Xu L; Li X; Li H; Zhao M
Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
[TBL] [Abstract][Full Text] [Related]
7. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
8. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
9. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
10. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
[TBL] [Abstract][Full Text] [Related]
11. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
12. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
13. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
14. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
[TBL] [Abstract][Full Text] [Related]
15. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
Xue Y; Morris JL; Yang K; Fu Z; Zhu X; Johnson F; Meehan B; Witkowski L; Yasmeen A; Golenar T; Coatham M; Morin G; Monast A; Pilon V; Fiset PO; Jung S; Gonzalez AV; Camilleri-Broet S; Fu L; Postovit LM; Spicer J; Gotlieb WH; Guiot MC; Rak J; Park M; Lockwood W; Foulkes WD; Prudent J; Huang S
Nat Commun; 2021 Sep; 12(1):5404. PubMed ID: 34518526
[TBL] [Abstract][Full Text] [Related]
16. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
17. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
[TBL] [Abstract][Full Text] [Related]
18. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
Medina PP; Sanchez-Cespedes M
Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
[TBL] [Abstract][Full Text] [Related]
20. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
